Aktive Positionen von David Urech
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Direktor/Vorstandsmitglied | 01.01.2011 | - |
Vorstandsvorsitzender | 01.01.2011 | - | |
Gründer | 01.01.2011 | - | |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 | - |
Karriereverlauf von David Urech
Ehemalige bekannte Positionen von David Urech
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von David Urech
University of Zurich | Undergraduate Degree |
University of Basel | Doctorate Degree |
Statistik
International
Schweiz | 5 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sektoral
Commercial Services | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
- Börse
- Insiders
- David Urech
- Erfahrung